Skip to main content
Signal8

Avacta Group Plc (AVCTF)

Sector: Biotechnology

Industry: Biotechnology

Avacta Group Plc logo

Avacta Group Plc

OTC:AVCTFHealthcare
CLOSED
Mkt Cap-
EV-
Float406.29M
O/S486.79M
VOL20K sh
$ Vol$15K
RVOL1.98×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 5, 20260.77000.77000.77000.770020,000
Oct 29, 20260.85000.85000.85000.8500200
Oct 7, 20260.85350.85350.85350.8535100
Analyst Coverage
Analyst Coverage
ConsensusSell
Price Target
Not available
Ratings Distribution
BUY
0
HOLD
0
SELL
1
TOTAL1
About

Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK.

The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms.

Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.

Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 486.79M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryGBGB
IPO Date-
Shares Outstanding486.79M
Authorized Shares
Float406.29M
52-Week Range
Volume
Average Daily Volume10.10K

30d Avg

10.10K

60d Avg

4.88K

90d Avg

4.96K

Earnings
Dividend History
No dividend history available